Found 15 matching trials
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors PHASE1 This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mi...
Show More Location
University of California Los Angeles
Learn More & Join Trial
MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer PHASE2 MEK is a critical member of the MAPK pathway involved in growth and surviva...
Show More Location
Pfizer Investigational Site
Learn More & Join Trial
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 PHASE2 This phase II open label study will evaluate adolescents (≥ 16 years of age...
Show More Location
Children's Hospital Los Angeles
Learn More & Join Trial
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma PHASE1 This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant...
Show More Location
St. Jude Children's Research Hospital
Learn More & Join Trial
Individual Patient Compassionate Use of Mirdametinib N/A This program is being offered on a patient by patient basis and will requir...
Show More Location
Multiple Locations
Learn More & Join Trial
PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors PHASE1 This research study is evaluating the experimental drug palbociclib in comb...
Show More Location
Dana Farber Cancer Institute
Learn More & Join Trial
Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. PHASE1 Monocentric study composed by 2 steps :
1. First step is a phase I with th...
Show More Location
Centre Georges-François Leclerc
Learn More & Join Trial
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2 Recent studies have demonstrated that growth of vascular malformations can ...
Show More Location
Peter MacCallum Cancer Centre
Learn More & Join Trial
MEK and MET Inhibition in Colorectal Cancer PHASE1 This trial is designed to try two new cancer drugs together for the first t...
Show More Location
Oxford University Hospital NHS Trust
Learn More & Join Trial
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib PHASE1 The purposes of this study are to determine:
* The pharmacokinetics (the a...
Show More Location
Clinical Pharmacology of Miami
Learn More & Join Trial